Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

First, a quick recap. We’ve had effective pre-exposure prophylactic (PrEP) drugs for HIV since 2012, but these must be taken either daily or just before a person is exposed to the virus.

A boxed warning is the most serious warning from the Food and Drug Administration (FDA). For details, see the “Before taking Descovy” section. Preexposure prophylaxis (PrEP) refers to taking ...

And because HIV is so frequently transmitted through sexual contact or intravenous drug use, the distribution of PrEP in particular has long raised objections among some conservatives who believe ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ...

Utilizing syringe service programs to provide comprehensive PrEP care shows promise for encouraging more people who inject ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...